title: Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
abstract: BACKGROUND
  The standard chemotherapy for Japanese patients with extensive disease of small-cell lung cancer (ED-SCLC) is cisplatin and irinotecan.
  
  
  METHODS
  Patients with untreated ED-SCLC were treated with nedaplatin (NP) at 50 mg/m(2) and irinotecan (CPT) at 50 mg/m(2) on days 1 and 8 every 4 weeks for four cycles.
  
  
  RESULTS
  Twenty-five patients were registered. Nineteen patients were male and six female, with a median age of 64 years (50-79 years). Two patients had a performance status of 2. Nineteen of them were able to receive 4 courses of NP and CPT chemotherapy. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia occurred in 8.0, 68.0, and 36.0 % of patients, respectively. Other grade 3 toxicities were SGOT, hyponatremia, fatigue, vomiting, diarrhea, hypotension, febrile neutropenia, oral hemorrhage, and pneumonia. Grade 4 fatigue occurred in one patient. There was no treatment-related death. The overall response rate was 100 %. The median progression-free and overall survivals were 6.6 and 16.0 months, respectively, and the 2-year survival rate was 28 %.
  
  
  CONCLUSIONS
  NP with CPT is effective and safe for patients with ED-SCLC.
authors.affiliation: Department of Thoracic Oncology Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. foshita@kcch.jp
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Oshita
authors.forename: Makiko
authors.initials: M
authors.lastname: Sugiura
authors.forename: Shuji
authors.initials: S
authors.lastname: Murakami
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kondo
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Saito
authors.forename: Kouzo
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000368:Aged; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality
chemical_list: D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002166:Camptothecin